NCT06207253 The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament
| NCT ID | NCT06207253 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | British University In Egypt |
| Condition | Endodontic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-11 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 48 participants in total. It began in 2025-11 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized clinical trial is to evaluate the capability of the material to exert bacterial reduction of diclofenac sodium versus of that calcium hydroxide paste when these materials are used as intracanal medications in permanent molar teeth with chronic apical periodontitis. The main question\[s\] it aims to answer are: • Will the diclofenac sodium (NSAIDs) possess antimicrobial efficacy to be used effectively as an intracanal medicament similar to that of calcium hydroxide in primary endodontic treatment? Participants will be allocated randomly into three equal groups by using computer generated randomization, according to the type of intracanal medication.
Eligibility Criteria
Inclusion Criteria: * Patients with teeth diagnosed with apical periodontitis * Periapical Index (PAI) ≥ 2 * The teeth are restorable Exclusion Criteria: * Teeth with immature roots * Non restorable teeth * Medically compromised patients with systemic complication that would alter the treatment. * Teeth with internal/external root resorption * Patient with an allergy to diclofenac sodium
Contact & Investigator
Shehab Eldin M Saber, doctoral
STUDY DIRECTOR
british university in Egypt- dentistry collage
Frequently Asked Questions
Who can join the NCT06207253 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Endodontic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06207253 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06207253 currently recruiting?
Yes, NCT06207253 is actively recruiting participants. Contact the research team at pg.summer92140015@bue.edu.eg for enrollment information.
Where is the NCT06207253 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06207253 clinical trial?
NCT06207253 is sponsored by British University In Egypt. The principal investigator is Shehab Eldin M Saber, doctoral at british university in Egypt- dentistry collage. The trial plans to enroll 48 participants.